Fool - Investing News
24 May 2026, 14:13 UTC · 2d ago
Source · https://www.fool.com/coverage/filings/2026/05/24/this-biotech-stock-is-up-355-one-fund-added-a-usd169-million-position-last-quarter/
Read source
Search tags
Story key points
4 claims · impact-rated
Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the fourth quarter of 2026. — A successful NDA submission is a primary value-defining catalyst for a biotech company moving toward commercialization.
+0.60Pivotal Phase 2b lupus data for envudeucitinib are expected to be released in the third quarter of 2026. — Clinical data readouts are high-volatility events that can significantly shift the valuation of biotech stocks.
+0.50Deep Track Capital established a new position in Alumis, acquiring approximately 6.77 million shares valued at an estimated $169.31 million. — Substantial institutional backing from a concentrated healthcare fund serves as a strong signal of confidence to other investors.
+0.40Alumis holds $569.5 million in cash and equivalents, providing a runway into the fourth quarter of 2027. — Strong liquidity reduces immediate dilution risk and ensures the company can fund its upcoming clinical and regulatory milestones.
+0.30Impact vectors
3 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
Deep Track Capital took a large new position and the company reported positive Phase 3 psoriasis data.
Mentioned only in a disclosure statement regarding the author's positions.
No ticker relationship head found.
